652 related articles for article (PubMed ID: 9271479)
1. Valvular heart disease associated with fenfluramine-phentermine.
Connolly HM; Crary JL; McGoon MD; Hensrud DD; Edwards BS; Edwards WD; Schaff HV
N Engl J Med; 1997 Aug; 337(9):581-8. PubMed ID: 9271479
[TBL] [Abstract][Full Text] [Related]
2. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.
Gardin JM; Schumacher D; Constantine G; Davis KD; Leung C; Reid CL
JAMA; 2000 Apr; 283(13):1703-9. PubMed ID: 10755496
[TBL] [Abstract][Full Text] [Related]
3. Operation for anorexigen-associated valvular heart disease.
Caccitolo JA; Connolly HM; Rubenson DS; Orszulak TA; Schaff HV
J Thorac Cardiovasc Surg; 2001 Oct; 122(4):656-64. PubMed ID: 11581595
[TBL] [Abstract][Full Text] [Related]
4. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine.
Gardin JM; Weissman NJ; Leung C; Panza JA; Fernicola D; Davis KD; Constantine GD; Reid CL
JAMA; 2001 Oct 24-31; 286(16):2011-4. PubMed ID: 11667938
[TBL] [Abstract][Full Text] [Related]
5. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE
N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.
Khan MA; Herzog CA; St Peter JV; Hartley GG; Madlon-Kay R; Dick CD; Asinger RW; Vessey JT
N Engl J Med; 1998 Sep; 339(11):713-8. PubMed ID: 9731086
[TBL] [Abstract][Full Text] [Related]
7. The longitudinal effects of fenfluramine-phentermine use.
Fleming RM; Boyd LB
Angiology; 2007; 58(3):353-9. PubMed ID: 17626991
[TBL] [Abstract][Full Text] [Related]
8. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.
Kancherla MK; Salti HI; Mulderink TA; Parker M; Bonow RO; Mehlman DJ
Am J Cardiol; 1999 Dec; 84(11):1335-8. PubMed ID: 10614800
[TBL] [Abstract][Full Text] [Related]
9. Valvular heart disease with the use of fenfluramine-phentermine.
Surapaneni P; Vinales KL; Najib MQ; Chaliki HP
Tex Heart Inst J; 2011; 38(5):581-3. PubMed ID: 22163141
[TBL] [Abstract][Full Text] [Related]
10. Further cases of valvular heart disease associated with fenfluramine-phentermine.
Graham DJ; Green L
N Engl J Med; 1997 Aug; 337(9):635. PubMed ID: 9280830
[No Abstract] [Full Text] [Related]
11. [Appetite suppressants and heart valve disorders].
Adams C; Cohen A
Arch Mal Coeur Vaiss; 1999 Sep; 92(9):1213-9. PubMed ID: 10533670
[TBL] [Abstract][Full Text] [Related]
12. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities.
Jollis JG; Landolfo CK; Kisslo J; Constantine GD; Davis KD; Ryan T
Circulation; 2000 May; 101(17):2071-7. PubMed ID: 10790349
[TBL] [Abstract][Full Text] [Related]
13. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience.
Teramae CY; Connolly HM; Grogan M; Miller FA
Mayo Clin Proc; 2000 May; 75(5):456-61. PubMed ID: 10807073
[TBL] [Abstract][Full Text] [Related]
14. Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs.
Burger AJ; Charlamb MJ; Singh S; Notarianni M; Blackburn GL; Sherman HB
Int J Cardiol; 2001 Jul; 79(2-3):159-65. PubMed ID: 11461737
[TBL] [Abstract][Full Text] [Related]
15. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.
Hensrud DD; Connolly HM; Grogan M; Miller FA; Bailey KR; Jensen MD
Mayo Clin Proc; 1999 Dec; 74(12):1191-7. PubMed ID: 10593346
[TBL] [Abstract][Full Text] [Related]
16. [Pulmonary hypertension and heart valve diseases induced by fenfluramine? Hypothesis or certitude? Myth or reality?].
Godeau P; Cherin P; Tellier P
Rev Med Interne; 1998 Oct; 19(10):700-3. PubMed ID: 9827440
[No Abstract] [Full Text] [Related]
17. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
Ryan DH; Bray GA; Helmcke F; Sander G; Volaufova J; Greenway F; Subramaniam P; Glancy DL
Obes Res; 1999 Jul; 7(4):313-22. PubMed ID: 10440587
[TBL] [Abstract][Full Text] [Related]
18. Valvular heart disease associated with fenfluramine-phentermine.
Rasmussen S; Corya BC; Glassman RD
N Engl J Med; 1997 Dec; 337(24):1773; author reply 1775. PubMed ID: 9411248
[No Abstract] [Full Text] [Related]
19. Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents.
Volmar KE; Hutchins GM
Arch Pathol Lab Med; 2001 Dec; 125(12):1555-61. PubMed ID: 11735689
[TBL] [Abstract][Full Text] [Related]
20. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.
Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT
N Engl J Med; 1998 Sep; 339(11):725-32. PubMed ID: 9731088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
